CORT
Income statement / Annual
Last year (2023), Corcept Therapeutics Incorporated's total revenue was $482.38 M,
an increase of 20.04% from the previous year.
In 2023, Corcept Therapeutics Incorporated's net income was $106.14 M.
See Corcept Therapeutics Incorporated’s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
Operating Revenue |
$482.38 M
|
$401.86 M
|
$365.98 M
|
$353.87 M
|
$306.49 M
|
$251.25 M
|
$159.20 M
|
$81.32 M
|
$50.29 M
|
$26.55 M
|
Cost of Revenue |
$6.48 M |
$5.39 M |
$5.28 M |
$5.58 M |
$5.50 M |
$5.22 M |
$3.55 M |
$2.06 M |
$1.36 M |
$882,000.00 |
Gross Profit |
$475.89 M |
$396.47 M |
$360.70 M |
$348.29 M |
$300.98 M |
$246.03 M |
$155.65 M |
$79.26 M |
$48.93 M |
$25.67 M |
Gross Profit Ratio |
0.99 |
0.99 |
0.99 |
0.98 |
0.98 |
0.98 |
0.98 |
0.97 |
0.97 |
0.97 |
Research and Development
Expenses |
$184.35 M
|
$130.99 M
|
$113.86 M
|
$114.76 M
|
$89.02 M
|
$75.25 M
|
$40.38 M
|
$23.84 M
|
$15.42 M
|
$18.37 M
|
General & Administrative
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Selling, General &
Administrative Expenses |
$184.26 M
|
$152.85 M
|
$122.36 M
|
$105.33 M
|
$100.36 M
|
$81.29 M
|
$62.42 M
|
$45.24 M
|
$36.95 M
|
$34.92 M
|
Other Expenses |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
Operating Expenses |
$368.61 M |
$283.84 M |
$236.22 M |
$220.09 M |
$189.38 M |
$156.54 M |
$102.79 M |
$69.08 M |
$52.37 M |
$53.29 M |
Cost And Expenses |
$375.09 M |
$289.22 M |
$241.50 M |
$225.67 M |
$194.88 M |
$161.75 M |
$106.35 M |
$71.14 M |
$53.73 M |
$54.17 M |
Interest Income |
$17.28 M |
$3.56 M |
$529,000.00 |
$3.40 M |
$5.07 M |
$2.66 M |
-$49,000.00 |
$0.00 |
$0.00 |
$0.00 |
Interest Expense |
$0.00 |
$3.56 M |
$0.00 |
$0.00 |
$5.07 M |
$2.66 M |
$49,000.00 |
$2.04 M |
$2.97 M |
$3.76 M |
Depreciation &
Amortization |
$1.04 M
|
$2.97 M
|
$3.07 M
|
$2.24 M
|
$2.17 M
|
$236,000.00
|
$106,000.00
|
$87,000.00
|
$155,000.00
|
$141,000.00
|
EBITDA |
$109.64 M
|
$112.63 M
|
$124.48 M
|
$128.20 M
|
$111.61 M
|
$89.50 M
|
$52.86 M
|
$10.27 M
|
-$3.29 M
|
-$27.48 M
|
EBITDA Ratio |
0.23 |
0.28 |
0.34 |
0.36 |
0.36 |
0.36 |
0.33 |
0.13 |
-0.07 |
-1.03 |
Operating Income Ratio
|
0.22
|
0.28
|
0.34
|
0.36
|
0.36
|
0.36
|
0.33
|
0.13
|
-0.07
|
-1.04
|
Total Other
Income/Expenses Net |
$17.28 M
|
$3.56 M
|
$529,000.00
|
$3.40 M
|
$5.07 M
|
$2.66 M
|
-$49,000.00
|
-$2.04 M
|
-$2.97 M
|
-$3.76 M
|
Income Before Tax |
$124.56 M |
$116.19 M |
$125.01 M |
$131.60 M |
$116.68 M |
$92.15 M |
$52.81 M |
$8.14 M |
-$6.41 M |
-$31.38 M |
Income Before Tax Ratio
|
0.26
|
0.29
|
0.34
|
0.37
|
0.38
|
0.37
|
0.33
|
0.1
|
-0.13
|
-1.18
|
Income Tax Expense |
$18.42 M |
$14.77 M |
$12.49 M |
$25.59 M |
$22.50 M |
$16.74 M |
-$76.32 M |
$0.00 |
$0.00 |
$0.00 |
Net Income |
$106.14 M |
$101.42 M |
$112.51 M |
$106.01 M |
$94.18 M |
$75.41 M |
$129.12 M |
$8.14 M |
-$6.41 M |
-$31.38 M |
Net Income Ratio |
0.22 |
0.25 |
0.31 |
0.3 |
0.31 |
0.3 |
0.81 |
0.1 |
-0.13 |
-1.18 |
EPS |
1.02 |
0.95 |
0.97 |
0.92 |
0.82 |
0.6 |
1.14 |
0.07 |
-0.06 |
-0.31 |
EPS Diluted |
0.94 |
0.87 |
0.89 |
0.85 |
0.77 |
0.6 |
1.04 |
0.07 |
-0.06 |
-0.31 |
Weighted Average Shares
Out |
$103.56 M
|
$106.79 M
|
$115.65 M
|
$115.41 M
|
$114.35 M
|
$125.68 M
|
$113.53 M
|
$110.57 M
|
$106.80 M
|
$100.98 M
|
Weighted Average Shares
Out Diluted |
$111.74 M
|
$115.97 M
|
$125.96 M
|
$124.19 M
|
$122.57 M
|
$126.69 M
|
$124.52 M
|
$116.14 M
|
$106.88 M
|
$100.98 M
|
Link |
|
|
|
|
|
|
|
|
|
|